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Abstract: Genetic activation of the class I PI3K pathway is very common in cancer. This mostly results
from oncogenic mutations in PIK3CA, the gene encoding the ubiquitously expressed PI3Kα catalytic
subunit, or from inactivation of the PTEN tumour suppressor, a lipid phosphatase that opposes
class I PI3K signalling. The clinical impact of PI3K inhibitors in solid tumours, aimed at dampening
cancer-cell-intrinsic PI3K activity, has thus far been limited. Challenges include poor drug tolerance,
incomplete pathway inhibition and pre-existing or inhibitor-induced resistance. The principle of
pharmacologically targeting cancer-cell-intrinsic PI3K activity also assumes that all cancer-promoting
effects of PI3K activation are reversible, which might not be the case. Emerging evidence suggests that
genetic PI3K pathway activation can induce and/or allow cells to tolerate chromosomal instability,
which—even if occurring in a low fraction of the cell population—might help to facilitate and/or drive
tumour evolution. While it is clear that such genomic events cannot be reverted pharmacologically, a
role for PI3K in the regulation of chromosomal instability could be exploited by using PI3K pathway
inhibitors to prevent those genomic events from happening and/or reduce the pace at which they
are occurring, thereby dampening cancer development or progression. Such an impact might be
most effective in tumours with clonal PI3K activation and achievable at lower drug doses than the
maximum-tolerated doses of PI3K inhibitors currently used in the clinic.
Keywords: PI 3-kinase; chromosomal instability; PI3K inhibitor; cancer; tumour evolution; centrosome
1. Introduction
In this section, we provide a general introduction to PI3K and chromosomal instability, and
describe in Section 2 how deregulated PI3K activity can affect chromosomal instability.
1.1. Class I PI3Ks–PIK3CA Mutation and Amplification
Class I PI3Ks are lipid kinases that signal downstream of tyrosine kinases, G protein-coupled
receptors and small GTPases such as Ras, cdc42 and Rac (Figure 1A) and convert the membrane-bound
lipid phosphatidylinositol(4,5)bisphosphate (PI(4,5)P2) to phosphatidylinositol(3,4,5)trisphosphate
(PI(3,4,5)P3; also known as PIP3). This lipid, together with its degradation product PI(3,4)P2, regulates
downstream signalling cascades involving Akt/PKB, mTORC1/2 and other proteins, ultimately inducing
anabolic metabolism, cell-cycle progression, migration and pro-survival functions [1,2]. PIP3 and
PI(3,4)P2 are both substrates for dephosphorylation at the 3′ position by the PTEN lipid phosphatase,
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effectively antagonising PI3K function. PTEN is a tumour suppressor whose frequent inactivation in
cancer disrupts the normal dampening of class I PI3K signalling [3].
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Figure 1. (A) Overview of class I PI3K signalling and genetic alterations in PI3K catalytic subunits in 
cancer. * Note that both wild-type and mutant PIK3CA alleles can be amplified in cancer [4]. A recent 
analysis showed that PIK3CA-mutant cancers frequently have more than one copy of the mutated 
PIK3CA gene and/or harbour a second PIK3CA variant [4]. (B) Frequency of PIK3CA alterations in a 
range of human cancers. Data are from cBioportal [5,6] (accessed June 2019). 
Mammals have four class I PI3K catalytic isoforms (p110α, β, γ and δ), encoded by four distinct 
genes, PIK3CA, PIK3CB, PIK3CG and PIK3CD (Figure 1A). The class IA subset of catalytic PI3Ks 
(p110α, β and δ) occur in a heterodimeric complex with a p85 regulatory subunit, of which there are 
three separate genes (PIK3R1, PIK3R2 and PIK3R3). This heterodimerisation keeps the p85/p110 
complex in an inactive state, which can be relieved by p85 binding to cell surface receptors. 
This perspective focuses on PIK3CA, the class I PI3K that is most frequently mutationally-
activated and/or gene-amplified in solid tumours (Figure 1B). In haematological malignancies, 
PIK3CA mutation or amplification is extremely rare (<0.1% in lymphoid and myeloid malignancies; 
cBioportal, accessed June 2019), with a slightly higher frequency of these events in PIK3CD (1% in 
lymphoid and myeloid malignancies; cBioportal, accessed June 2019), which is almost exclusively 
constituted by mutations in PIK3CD in diffuse large B-cell lymphoma. No consistent overexpression 
of class I PI3K subunits has been observed in haematological malignancies. 
Common ‘oncogenic’ hotspots of PIK3CA mutations are found in the helical (E542K, E545K) and 
C-terminal domains (H1047R) of p110α [7]. Oncogenic mutations in PIK3CA lead to a constitutive de-
inhibition of the p110α/p85 complex [8]. Such de-inhibition of the p85/p110 complex can also be 
achieved by mutations in the genes encoding the p85 subunits [9]. 
The non-mutated, wild-type PIK3CA gene is also frequently amplified in cancer, such as in lung 
squamous carcinoma where this occurs as part of amplification of the 3q genomic locus, the most 
common genomic aberration in this cancer [10]. It is currently unclear whether amplification of 
PIK3CA on its own leads to enhanced signalling. Whereas expression of oncogenically-mutated 
PIK3CA in cell-based studies leads to PI3K pathway activation (as assessed by phosphorylation of 
Akt/PKB), this is most often not the case upon overexpression of wild-type PIK3CA (see, for example, 
[11,12]). Overexpression of wild-type PIK3CA did not transform chicken embryo fibroblasts, in 
contrast to oncogenically mutated PIK3CA [13]. It is therefore possible that additional alterations in 
the pathway are required in order for PIK3CA amplification to result in PI3K pathway activation. In 
this context, recent data in squamous lung cancer show that PIK3CA amplification frequently co-
occurs with amplification of Akt2 on chromosome 19 [14]. Evidence for a possible dosage dependency 
of genetic PI3K pathway activation in cancer, including for PIK3CA mutation [15,16], has recently re-
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This is in line with other studies showing pervasive selection in cancer for oncogenic mutant allele
imbalance [17,18].
In the text below, we will refer to PIK3CA mutation or amplification as ‘PIK3CA activation’.
1.2. Chromosomal Instability, Whole-Genome Doubling and Aneuploidy-A Cellular Stress
1.2.1. Chromosomal Instability (CIN)
Chromosomal Instability (CIN) is the dynamic process of chromosomal alterations occurring at
an elevated rate, in the form of structural or numerical changes. Numerical CIN has been attributed to
mitotic defects such as erroneous kinetochore–microtubule attachments, compromised centromere
geometry, supernumerary centrosomes, impaired spindle assembly checkpoint, and sister chromatid
cohesion [19]. Structural CIN has been linked to pre-mitotic processes such as replication stress,
failures in DNA repair and defective telomere maintenance. It is manifested by the presence of
duplicated, deleted or rearranged chromosome fragments, acentric fragments (centromere absent),
dicentric chromosomes (two centromeres) and chromatin bridges, all of which compromise genomic
integrity. The investigation of the possible links between pre-mitotic and mitotic defects is an active
area of research [20,21]. Importantly, oncogenic activation of several signalling pathways has been
shown to contribute to the induction of CIN by compromising the above cellular processes [22]. CIN is
thought to allow cancer cells to adapt to selective pressures during tumour evolution, metastasis and
treatment [23,24], due to simultaneous dosage changes in a large number of genes.
1.2.2. Whole Genome Doubling (WGD)
Whole Genome Doubling (WGD), the duplication of the entire chromosome complement, is
prevalent in cancer and a significant proportion of human tumours (over 50% for breast and lung)
undergo WGD during development [25,26]. Mechanisms implicated in WGD include cytokinesis
failure at the end of mitosis, endoreduplication and cell fusion [27]. In most cases, tetraploid cells are
genomically unstable and accumulate numerical and/or structural chromosomal abnormalities, which
can contribute to tumour heterogeneity and evolution. A stochastic model, based on the potency and
chromosomal distribution of oncogenes and tumour suppressor genes, suggested that WGD represents
a path to a commonly observed near-triploid state [28]. Recent analyses have provided strong evidence
that WGD provides a buffering effect in cancer cells against the effects of gene or chromosome losses or
deleterious mutations [29].
1.2.3. Aneuploidy, Cellular Stress and the CIN Paradox
Aneuploidy, referring to an abnormal number of chromosomes in a cell, imposes cellular stress
due to imbalanced gene expression and increased burden on protein turnover machinery. This can
lead to impaired proliferation [30–35] and can also induce cell death or senescence, often dependent
on the level of CIN [36–38]. Studies in yeast suggest that perturbation of the stoichiometries of
protein complexes, caused by the presence/absence of additional chromosomes, contributes to the
so-called proteotoxic stress response [39,40]. Mammalian cells with an abnormal karyotype have been
shown to activate the process of autophagy and lysosome-mediated protein degradation, possibly
to cope with this stress [34,35]. Aneuploid yeast and human cancer cells also exhibit a sustained
hypo-osmotic-like response, characterised by plasma membrane stress and impaired endocytosis, with
an ensuing remodelling of cellular metabolism and a dependency on ubiquitin-mediated endocytic
recycling of nutrient transporters [40].
It is not clear whether autophagy is a consequence or a cause of chromosomal aberrations.
Autophagy has been implicated in preventing chromosomal instability and associated tumourigenesis,
with impaired autophagy-promoting gene amplification, chromosome instability and aneuploidy [41].
A recent study suggested that autophagy is responsible for the cell death occurring at replicative
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crisis [42], underlining a tumour-suppressive role for autophagy at an early stage of immortalisation
and malignant transformation.
It has now also become clear that the rate of chromosome segregation errors occurring in cancer
cells must be within a sustainable range to avoid cell death associated with extreme karyotypic
changes [31,32]. This helps to explain the so-called CIN/aneuploidy paradox [31], whereby extreme
CIN is tumour-suppressive. Aneuploidy is thus not cancer-promoting per se, and low levels of
CIN are now viewed as more biologically relevant for driving tumour-evolution and adaptation. Of
note, deregulation of the tumour suppressor TP53, including through loss of TP53 expression or
gain-of-function mutations in TP53, is a well-known tolerance mechanism towards aneuploidy [43–46].
1.3. Microtubules and the Mitotic Spindle
Microtubules are protein structures composed of α/β-tubulin heterodimers in a head-to-tail
arrangement. They nucleate from centrosomes (see Section 1.4 below) and are involved in many
cellular processes such as mitosis, intracellular transport and cell motility [47–49]. Microtubules are
polarised structures with a fast-growing, highly-dynamic plus-end (the main site of elongation) and a
minus-end, which is slow growing, stable and often anchored at the centrosome. Microtubules are
characterised by dynamic instability, undergoing cycles of growth and shrinkage, and are regulated by
a broad range of stabilising and destabilising factors [47–49].
Chromosome segregation requires that chromosomes form attachments to the plus-ends of
parallel microtubule bundles via kinetochores (Figure 2A). These are large multimeric protein
complexes associated with the centromere of chromosomes that regulate the dynamics of the associated
microtubules and power chromosome motion. The microtubule–kinetochore interface is highly
dynamic, with microtubules growing and shrinking at the site of attachment. The correct attachment
of sister kinetochores to microtubules emanating from opposite centrosomes is essential for the fidelity
of chromosome segregation. Increased microtubule stability and defects in correction mechanisms
of erroneous microtubule–kinetochore attachments lead to chromosome mis-segregation during cell
division [23,50]. Altered microtubule assembly rates within mitotic spindles also impact CIN in cancer
cells [51].
Biomolecules 2019, 9, 331 4 of 18 
It as  ls  ec e cle r t t t  r t  f s  s re ati  errors cc rri  i  c cer 
cells st be ithin a sustainable range to avoid ce l death associated ith extre e karyoty ic 
c a s [31,32]. i  l  t  e l i  t e so-calle  I /a e l i  r  [ ], ere  extre e 
I   i . Aneuploidy is thus not cancer-promoting per se, and low leve s of CIN 
are now viewed as more biologically re evant for driving tumo r-evoluti n and daptation. Of note, 
deregulation of the tumour suppressor TP53, including through loss of TP53 expression or gai - f-
fu ction mutations in TP53, is a well-known tolerance me hanism towards aneuploidy [43–46]. 
1.3. icrotubules and the itotic Spindle 
icrotubules are protein structures co posed of α/β-tubulin heterodi ers in a head-to-tail 
arrange ent. They nucleate fro  centroso es (see Section 1.4 below) and are involved in any 
cellular processes such as itosis, intracellular transport and cell otility [47–49]. icrotubules are 
polarised structures with a fast-growing, highly-dynamic plus-end (the main site of elongation) and 
a minus-end, which is slow growing, stable and often anchored at the centrosome. icrotubules are 
characterised by dynamic instability, undergoing cycles of growth and shrinkage, and are regulated 
by a broad range of stabilising and destabilising factors [47–49]. 
Chro oso e segregation requires that chro oso es for  attach ents to the plus-ends of 
parallel icrotubule bundles via kinetochores (Figure 2A). These are large ulti eric protein 
co plexes associated with the centromere of chro osomes that regulate the dynamics of the 
associated microtubules and power chromosome motion. The microtubule–kinetochore interface is 
highly dynamic, with microtubules growing and shrinking at the site of attachment. The correct 
attachment of sister kinetochores to microtubules emanating from opposite centrosomes is essential 
for the fidelity of chromosome segregation. Increased microtubule stability and defects in correction 
mechanisms of erroneous microtubule–kinetochore attach ents lead to chromosome mis-
segregation during cell division [23,50]. Altered microtubule assembly rates within mitotic spindles 
also impact CIN in cancer cells [51]. 
 
Figure 2. Deregulation by PIK3CA activation of microtubule (A) and centrosome biology (B) in 
relation to the regulation of the mitotic spindle. 
1.4. Centrosomes 
In proliferating cells, two complex microtubule structures called centrioles, embedded within a 
matrix of proteins known as the pericentriolar material (PCM), form the centrosome, which functions 
Figure 2. Schematic depicting the mitotic spindle in wild-type cells (A) and how this is deregulated in
cells with PIK3CA mutation/amplification (B).
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1.4. Centrosomes
In proliferating cells, two complex microtubule structures called centrioles, embedded within a
matrix of proteins known as the pericentriolar material (PCM), form the centrosome, which functions
as the main microtubule-organising centre (MTOC). In many non-proliferating cells, centrioles migrate
to the cell surface to template the assembly of a cilium.
A cell normally has one centrosome, which is duplicated once per cell cycle. Aberrant cellular
centrosome numbers are associated with aneuploidy, CIN and cancer [52–54]. While multipolar
divisions and the resulting aneuploidy often lead to non-viable progeny [55–58], many cells with
supernumerary centrosomes either cluster them into two spindle poles, or selectively inactivate
extra centrosomes to enable bipolar divisions [59–61]. Centrosome clustering efficiency depends
on the cell type. For example, epithelial cells have low clustering efficiency and do not tolerate
extra centrosomes [62]. E-cadherin loss leads to increased cortical contractility, which is sufficient to
promote centrosome clustering, facilitating the proliferation and survival of cancer cells with extra
centrosomes [62]. Importantly, supernumerary centrosomes and multipolar spindle geometry increase
the probability of creating merotelic attachments (a single kinetochore attached to two spindle poles),
which is a major mechanism of aneuploidy and chromosomal instability in cancer cells [57,63,64].
Recent findings have reinforced the importance of centrosome amplification in cancer
initiation [64–67]. It is important to mention, however, that there are several human conditions
with rampant centrosome amplification, for example, due to mutations in centrosomal genes leading
to microcephaly, dwarfism and ciliopathies, all of which are without a discernible increase in cancer
(see, for example, [68]; reviewed in [69–71]).
In addition to their function as a MTOC, centrosomes have also been postulated to act as signalling
hubs that integrate and coordinate a range of signalling pathways. This hypothesis is based on
the observation that many signalling components, including kinases and phosphatases, have been
associated with centrosomes and spindle poles [72–74] (see also Table 1; Table 2).
Table 1. PI3K pathway components found in centrosome/primary cilium.
PI3K Pathway Component References Additional Information
p85 regulatory subunit of PI3K [75,76] p85 can associate with the centrosome in aninsulin-dependent manner
Akt/PKB
[77] Akt/PKB is phosphorylated during mitosis and ispresent in the centrosome
[78] T308-phosphorylated Akt/PKB is present in basalbody of primary cilia
[79]
S473-phosphorylated Akt/PKB is present in basal
body of primary cilia. Akt/PKB interacts with and
phosphorylates the ciliary protein Inversin.
[80] Akt/PKB-inhibition prevents recruitment of PTEN tomitotic centrosomes
TSC1/TSC2 (TSC2 is an
Akt/PKB substrate) [81]
TSC1 is present in centrosome. Phosphorylated TSC1
and phosphorylated TSC2 co-immunoprecipitate
with Plk1
GSK3β (Akt/PKB substrate) [77] Phospho-GSK-3 at the centrosomes upon entryinto mitosis
PTEN [82]
Phosphatase-independent (scaffold function) of
PTEN is recruited to pre-mitotic centrosomes in a
Plk1-dependent fashion
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Table 2. Akt/PKB substrates found in centrosome/primary cilium.
Akt/PKB Substrate References Additional Information
TSC1/TSC2 (TSC2 is an
Akt/PKB substrate) [81]
TSC1 is present in centrosome. Phosphorylated TSC1 and
phosphorylated TSC2 co-immunoprecipitate with Plk1
GSK3β [77] Phospho-GSK3 at the centrosomes upon entry into mitosis
Inversin [79]
Akt/PKB interacts with and phosphorylates the ciliary
protein Inversin—dimerisation. Co-localisation of Inversin
and phosphorylated-Akt/PKB at the basal body is
augmented by PDGF-AA.
TEIF [83] TIEF is a potential centrosome component
Girdin [84,85] Girdin may localise to centrosomes
2. PI3K Pathway Activation and CIN/WGD
2.1. PIK3CA/Akt
Several oncogenic signalling pathways ranging from Ras and Raf [86–92] to Rb, Notch and many
others have been shown to contribute to the induction of CIN (reviewed in [22]). We here propose a
new potential CIN-inducing pathway, mediated by PIK3CA-AKT, which may also include downstream
MTOR signalling.
We recently reported that expression of the PIK3CAH1047R mutant can lead to centrosome
amplification (in mouse embryonic fibroblasts (MEFs), the MCF10A immortalised breast cell line
and in mouse tissues) and increased in vitro tolerance to WGD (in MEFs) [93], indicating that PI3K
activation might be involved in CIN (Figure 2B). Signalling pathways involved in PIK3CAH1047R-driven
centrosome amplification include AKT, ROCK and CDK2/Cyclin E-nucleophosmin [93]. Overexpression
of Akt/PKB has been shown to induce supernumerary centrosomes/aneuploidy in cell lines [94,95].
There is also some preliminary evidence in HeLa cells suggesting that mTOR hyperactivation may
induce polyploidy [96].
It is of interest to note that ∼30% of the phosphopeptides differentially-phosphorylated in
PIK3CAH1047R MEFs compared to control cells belong to proteins associated with ‘cytoskeleton,
cell-cycle and centrosome function’ [97]. In addition, expression of a gene set that controls mitosis
(microtubule and mitotic spindle regulators) was found to be enriched in PIK3CAH1047R MCF10A
breast cancer cells [98]. Interestingly, this gene set was not enriched in MCF10A cells that had lost
PTEN [98]. A study mapping the dynamic protein–protein interaction network within the core insulin
signalling pathway in Drosophila also found significant enrichment for proteins involved in ‘centrosome
duplication’ following 10 and 30 min of insulin stimulation [99].
Indirect evidence for a role for PI3K in centrosome biology was previously found in human
HeLa and HCT116 cell lines, in which stable transfection of an oncogenic c-Met tyrosine kinase
receptor induced centrosome amplification in a PI3K-dependent manner, independent of the MAPK
pathway [100]. At the time, it was unclear whether these observations were artefacts of cell-based
overexpression studies. Our demonstration that physiological induction of PIK3CAH1047R (i.e., in the
heterozygous state and expressed from the endogenous promotor) can induce centrosome amplification
and aneuploidy [93] more firmly establishes this biological role of mutant PI3K. In fact, PI3K also controls
tetraploidisation under physiological conditions: in rodents, modulation of insulin concentration, and
consequently Akt/PKB activity, orients hepatocytes into a specific cell-cycle program, leading to the
generation of binucleated tetraploid cells [101].
PIK3CA mutation is very common in breast cancer, where it appears to be an early, clonal event [93].
Moreover, in genome-doubled breast cancers, the majority of PIK3CA mutations precede the genome
duplication event, with PIK3CA mutations showing a tendency to be mutually exclusive with mutations
in TP53 [93], a known tolerance mechanism towards genome doubling [43–45]. These data indicate a
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potential role of PIK3CA mutation as a tolerance mechanism for genome doubling in breast cancer,
independent of the p53 pathway. Additional studies are required to determine whether oncogenic
PIK3CA activation might function as a CIN inducer, as tolerance mechanism to CIN induced by other
stimuli, or both.
2.2. PTEN
PTEN loss has been extensively linked to CIN, a biological role that is largely dependent on the
scaffolding rather than the phosphatase function of PTEN [102], and therefore mostly independent of
PI3K/Akt activity. Given that these PTEN effects can therefore not be modulated by pharmacological
intervention targeting PI3K, these will not be described here. For an excellent review on the functions
of PTEN in the maintenance of genome integrity, the reader is referred to [102].
3. Potential Molecular Mechanisms Underlying PIK3CA-Related CIN
It is possible that genetic PIK3CA-activation, due to its constitutive signalling (as opposed to
transient PI3K signalling upon growth factor stimulation), leads to a deregulation of cell biological
processes in such a way that these become cancer-promoting.
3.1. Cell-Cycle Block by Constitutive PI3K (Over) Activation?
PI3K/Akt signalling regulates the activity and expression of several key proteins involved in
cell-cycle progression, including cyclin D and the cyclin-dependent kinase inhibitor proteins p21 and
p27 (reviewed in [103–105]). PI3K activity oscillates during the cell cycle [106–109] suggesting that
pathway signalling dynamics may be important for phenotypic regulation. Consistent with this notion,
forced expression of constitutive PI3Kα alleles blocks efficient cell-cycle progression [110,111], which
can even lead to cell death under serum-free conditions [110]. A study using single-cell analysis
provided further evidence that high PI3K activity cannot be sustained, with cells exhibiting high Akt
activation in the cell population undergoing senescence [112]. Mechanisms implicated in a PI3K-driven
cell-cycle block include a lack of downregulation of the cyclin E-Cdk2 complex, which normally
disappears after entry into S phase of the cell cycle [110], and an inability to increase the activity of
the transcription factor FOXO1 downstream of Akt, which is necessary for cell-cycle completion [111].
The complexity of PI3K signalling dynamics is, however, poorly captured by conventional studies
of the pathway. This has spurred the development of computational models, with a recent Boolean
model predicting the mechanistic basis for cellular PI3K pathway oscillations as well as their impact
on cytokinesis and cell death [113].
In the studies mentioned above [110–112], the long-term fate of cells undergoing cell-cycle
blockade has not been investigated. Should these cells manage to exit this cell-cycle block, this might
involve cytokinesis defects and chromosomal segregation errors, amongst others. Even if this occurred
at low frequency in a cell population, if it were to take place continuously, this process could give
rise to cell clones with altered genetic constellations. These cells could then seed or maintain cancer
development, akin to the ability of drug-tolerant persister cells—a small fraction of the bulk cancer cell
population—to serve as a latent reservoir of cells for treatment-resistant tumour growth [114,115].
At present, it is not clear whether the observed defects in cell-cycle progression are an artefact
of forced overexpression of supra-physiologically active PI3K constructs, or whether this would also
occur upon endogenous oncogenic PIK3CA activation. In this regard, we did not find evidence
for cell-cycle blockade in MEFs expressing an endogenous heterozygous PIK3CAH1047R allele [93].
Oncogenic activation of PI3K signaling has also been shown to elicit senescence in some cellular
contexts [112,116,117] but not in others [93,118]. Other than being context-dependent, evidence has
been presented that PIK3CA activation is a weaker inducer of senescence than oncogenic Ras [119].
However, there is increasing evidence that genetic PI3K pathway activation in cancer might
be a graded event, similar to observations of oncogenic K-Ras [18], with the presence of more than
one mutant copy of PIK3CA and/or genetic activation of other PI3K pathway components seen in
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established tumours [4]. It is tempting to speculate that cell-cycle aberrations and possibly CIN might
be induced beyond a certain threshold of sustained high PI3K pathway activation. In other words, in
addition to disruption of the duration of PI3K pathway activation, the strength of the signal might also
be of importance in the context of CIN.
3.2. Impact of PI3K on Microtubules and the Mitotic Spindle
Growth factor-stimulated PI3K activation [120] or oncogenic PIK3CA activation [121] have been
shown to lead to microtubule stabilisation, a phenomenon that when sustained, can compromise
genome integrity. Indeed, stabilisation of kinetochore–microtubule attachments at prometaphase or
metaphase, by depletion of the kinesin-13 microtubule depolymerases Kif2b or MCAK, prevents the
release of misoriented microtubule attachments, leading to merotelic attachments and other segregation
effects [50].
Molecularly, the CLASP microtubule-associated proteins have been shown to colocalise at
microtubule plus-ends in a PI3K/GSK3β-dependent manner, resulting in microtubule stabilisation
at the leading edge of motile fibroblasts [122]. Stathmin, a microtubule-destabilising protein whose
activity is known to be reduced by phosphorylation on Ser-38 [123], is also of potential relevance in this
context. Indeed, high phospho-Ser38-Stathmin is associated with PI3K pathway activation in aggressive
endometrial cancer [124], with PI3K pathway inhibitors dampening Ser38 phosphorylation [125].
GSK3β is a kinase of potential relevance to the regulation of microtubule stabilisation by PI3K.
This Ser/Thr kinase is constitutively-active in cells, but becomes inactivated upon phosphorylation
by Akt [126]. In addition to its role in metabolic/insulin signalling, GSK3β is involved in
microtubule regulation, such as through the phosphorylation of MAPs (MT-associated proteins),
APC (anaphase-promoting complex) and CLASPs and, when active, generally decreases microtubule
stability. It is possible that sustained GSK3 inactivation, due to constitutive PI3K/Akt activity upon
PIK3CA activation, contributes to microtubule stabilisation. Although early work linked GSK3β and
microtubules upon transient PI3K/Akt stimulation by growth factors [77,127,128], GSK3β has since
been largely ignored in the PI3K field.
PIP3 has been shown to be generated at the midcortex in metaphase cells and to be involved in
spindle orientation [129–131]. The Carrera group further showed an involvement of p110α in these
phenomena, with p110α becoming activated at mitosis entry and regulating early mitotic events,
such as PIP3 generation, prometaphase progression and spindle orientation [131]. The latter could
involve the regulation of cortical microtubule attachment complexes by p110α (Figure 2B). Indeed,
in HeLa cells, inhibition of p110α dampens cortical clustering of LL5β, a microtubule-anchoring
protein [132] that attaches EB1/CLASP-bound microtubule plus-ends to the cell cortex [133]. LL5β
contains a PIP3-binding PH domain and is thus a putative downstream effector of p110α. Upon PI3K
activation, LL5β in complex with CLASP relocalises to the plasma membrane and orientates stabilised
microtubules towards the leading edge [133].
Of note, cytoplasmic PTEN has also been reported to be mainly associated with microtubules,
which may be important in regulating its function [134].
It is worth pointing out the existence of conflicting data on the impact of PI3K-pathway mutation
on cellular sensitivity to microtubule-deregulating anti-mitotic drugs (on their own or in combination
with PI3K inhibitors) [11,120,135]. Many studies used early generation pan-PI3K/mTOR inhibitors
and cancer cell lines with complex genetic backgrounds, precluding a clear interpretation of the
observations made. In addition, several studies have used the PI3K inhibitor BKM120/Buparlisib,
which directly binds to microtubules and interferes with microtubule polymerisation [136,137].
3.3. Impact of PI3K on Centrosomes (and Vice Versa)
Recent data have implicated PI3K activation in centrosome amplification, such as by PIK3CAH1407R
activation in MEFs [93]. Centrosome amplification induced by the oncogenic c-Met-tyrosine
kinase receptor has been shown to occur via PI3K/Akt, independent of the MAPK pathway [100].
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Moreover, EGF controls centrosome separation through Akt, independent of MEK, MAPK or mTORC1
pathways [138].
PIK3CA activation is known to promote a mesenchymal morphology in a range of epithelial
cell lines [117,139]. Given that epithelial cells are innately inefficient at centrosome clustering [62],
such PIK3CA-induced epithelial-to-mesenchymal transition and altered cortical tension may enable
these cells to efficiently cluster supernumerary centrosomes [62] and divide in the wake of misaligned
chromosomes, pre-disposing them to CIN. On the other hand, persistent proliferation of cells undergoing
epithelial-to-mesenchymal transition has been shown to lead to genomic instability [140].
Interestingly, several PI3K pathway components (Table 1) and substrates for the PI3K-activated
kinase Akt/PKB (Table 2) can be found in centrosomes. Members of the transforming acidic coiled-coil
(TACC) family of proteins, implicated in centrosome regulation and cancer, are of particular interest
in this context [141,142]. Indeed, TACC1, a centrosome-localised microtubule-binding protein,
was recently identified as a top hit in a genome-wide shRNA screen for genes that convert
PI3K inhibitor-induced cytostasis to cytotoxicity, selectively in PIK3CA-mutant cells [143]. This
is in line with data indicating that TACC1 overexpression protects cells from cytostasis induced
by PI3K inhibition [144]. This differential sensitivity may relate to a vulnerability generated by
microtubule/centrosome changes in PIK3CA-mutant cells. Moreover, the TACC3 isoform interacts
with TSC2 [145], a bona fide Akt substrate, suggesting a possible interplay between PI3K/Akt and
TACC/centrosome pathways. FGFR-TACC fusion proteins, generated by gene translocations in cancer,
have also been shown to display oncogenic activity, to induce chromosomal segregation defects and to
trigger aneuploidy [146].
Several other studies support a reciprocal relationship between the PI3K pathway and centrosomal
regulation. An RNAi screen in Drosophila thus identified proteins involved in the centrosome cycle as
regulators of acute insulin-dependent AKT activation [99]. Microtubule acetylation has also recently
been linked to sequestration and inhibition of AKT [147]. Further understanding of this intricate
crosstalk is required to determine how it may influence or be influenced by oncogenic PIK3CA-induced
centrosome amplification.
4. Potential Therapeutic Exploitation in Cancer Prevention and Dampening of Tumour Evolution
At present, there are no therapies aiming to interfere with tumour evolution [23]. As argued
above, it is possible that the generation and/or tolerance of CIN is a cancer-promoting activity of
oncogenic PI3K activation, resulting in irreversible genetic alterations and a greater ability to adapt to
selective pressures, due to clonal diversification [23]. This potentially pre-disposes cells to aneuploidy,
setting the scene for cooperation with other cancer-promoting genetic lesions and fostering cell-to-cell
variation, the substrate for tumour evolution. This would potentially allow PIK3CA activation to act as
a continuous driver/facilitator of genetic changes in cancer, but also offer a druggable opportunity to
interfere with tumour evolution. An important question is which cancers would potentially benefit
from interfering with PI3K activity to block CIN, and whether such an approach would require the
maximum-tolerated doses of PI3K inhibitors that are currently used in the clinic.
With regards to the first question, it is of relevance to note that mutation of PIK3CA is an early
clonal event, occurring before WGD, in both breast cancer [93] and in colon cancer [148]. This is also the
case for PIK3CA amplification (as part of a 3q arm amplification) in lung squamous cell carcinoma [149].
In some cases of colon cancer, PIK3CA mutation was estimated to have occurred at least a decade before
cancer diagnosis [148]. Especially upon early diagnosis of the presence of such genetic alterations, for
example, using liquid biopsies that can detect PIK3CA mutation [150], it is tempting to speculate that
administration of low doses of PI3K pathway inhibitors could be used as a strategy to prevent cancer
development and/or progression [151].
In other cancer types where PI3K pathway activation is not clonal such as in renal cell carcinoma,
evidence indicates that the PI3K–AKT–mTORC1 pathway often becomes recurrently activated at
multiple branch points during tumour evolution [152]. This occurs in separate subclones within the
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same tumour [152] and is an example of so-called parallel tumour evolution that converges upon PI3K
activation [153]. In these cancers, interference with PI3K signalling as part of a maintenance therapy
might also dampen tumour evolution.
With regards to the question of drug dose, it would be challenging to administer high doses of
PI3K inhibitors in a preventative or maintenance setting, due to toxic side effects and cost. Moreover,
high doses of PI3K inhibitors aiming to wipe out all cellular PI3K activity often give rise to feedback
PI3K re-/over-activation, which would clearly be undesirable in this context. Although this remains
to be proven, it is possible that oncogenic PIK3CA leads to low-level PI3K signalling, compared
to growth-factor-stimulated PI3K activation. This would mean that low doses of PI3K inhibitors
might allow the specific dampening of oncogenic PI3K signalling while still allowing normal PI3K
signalling, and thereby interfere with tumour evolution. The feasibility of such low-dose PI3K
inhibitor treatment is supported by observations in patients with so-called PIK3CA-related overgrowth
syndrome (PROS), caused by embryonic acquisition of mosaic activating PIK3CA mutations [154]. In
this context, long-term administration of low doses of a PI3Kα-selective inhibitor have led to dramatic
improvements in disease severity with negligible or no side effects [155], with some patients having
been on a low dose PI3Kα inhibitor for up to 3.5 years (Guillaume Canaud, personal communication).
It is important to emphasise that administration of such a low dose of a PI3K inhibitor is not
expected to induce anti-proliferation or cancer regression in advanced cancers, which would require
standard anti-cancer therapies such as chemotherapy or surgery.
5. Concluding Remarks
In this perspective, we have summarised the evidence for a potential role of PIK3CA activation
in the induction and/or tolerance of CIN. Such a role could be indirect; for example, by providing
survival signals to cope with the cell stress imposed by CIN. A role in CIN could also derive from
the sustained pathway stimulation by PIK3CA activation (which might disrupt cellular processes
that normally require cyclical regulation such as cell-cycle progression) and/or the dose level of PI3K
pathway activation.
A clear role of PIK3CA in CIN may not have been uncovered to date because PI3K research has
mainly focused on the analysis of bulk cell populations, using either PI3K inhibitors, experimental
conditions of acute signalling often by supra-physiological doses of growth factors, and established
PIK3CA mutant cells that have adapted to constitutive PI3K activation. It is clear that single cell
analyses will be critical to capture possible CIN and cell heterogeneity induced by PIK3CA activation,
in addition to appropriate cell- and tissue-based models such as 2D/3D cultures [156] and inducible
models of PIK3CA activation. Bioinformatic analysis of human tumours may also allow the correlation
of the timing of PIK3CA activation with CIN in whole tissues. Together, such data could underpin the
potential exploitation of this knowledge in cancer prevention, or dampening cancer progression using
PI3K pathway inhibitors. Given that other growth-factor-related oncogenes such as Ras and Raf might
also regulate CIN [86–92], one could even speculate that a cocktail of oncogene pathway inhibitors,
given at low doses, might be an effective way to dampen cancer evolution (reviewed in [151]).
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